- Completed
NCT03448978: Phase 1/2 - Descartes-08 - anti-BCMA-CAR-mRNA-trans. auto CD8+ T cells in Myeloma
Updated: May 23, 2022
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
Combined Phase I-Phase II Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma
Sponsor
Multiple Locations
ClinicalTrials.gov Identifier: NCT03448978
Official Title: Combined Phase I-Phase II Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma
First Posted : February 28, 2018
Click here for details on ClinicalTrials.gov
autologous anti-BCMA-CAR-mRNA-transfected CD8+ T lymphocytes
anti-BCMA-CAR-mRNA-transfected autologous CD8+ T cells
autologous anti-BCMA-CAR-mRNA-transfected CD8-positive T cells
autologous anti-BCMA-CAR-mRNA-transfected CD8+ T cells
Descartes-08
Biological: Descartes-08
Biological: Descartes-08
Drug: Fludarabine
Drug: Cyclophosphamide
Experimental:
Descartes-08 plus fludarabine/cyclophosphamide pretreat
Maryland: The Center for Cancer and Blood Disorders
Bethesda, Maryland, United States, 20817
Oklahoma: University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
Virginia: Virgina Cancer Specialists
Fairfax, Virginia, United States, 22031
Locations
United States, Maryland
United States, Oklahoma
United States, Virginia